initial public offerings (IPOs) trading on American exchanges

Friday, December 7, 2018

Synthorx (THOR) began trading on the Nasdaq on 7 December 2018

Update Dec 9, 2019:  Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 billion


The biopharmaceutical company Synthorx designs proteins for targeted therapeutic modulation of tumors and autoimmune disorders.

Synthorx opened for trading at $15.40 after pricing IPO at $11.
The company issued 9.1 million shares

No comments:

Post a Comment